Published in Can Med Assoc J on April 29, 1961
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science (1984) 8.18
Culture of human malaria parasites Plasmodium falciparum. Nature (1976) 5.34
Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol (1990) 3.11
Evidence for differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and Plasmodium knowlesi. J Exp Med (1977) 2.92
Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion. J Clin Invest (1987) 2.91
A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycophorin A. J Cell Biol (1992) 2.19
Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol (1983) 2.03
Localization of the 175-kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum merozoites. Mol Biochem Parasitol (1992) 1.80
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun (2000) 1.77
Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc Natl Acad Sci U S A (1986) 1.77
Plasmodium falciparum strain-specific human antibody inhibits merozoite invasion of erythrocytes. Am J Trop Med Hyg (1984) 1.62
Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun (1983) 1.60
Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasitol (1990) 1.55
Plasmodium falciparum antigens synthesized by schizonts and stabilized at the merozoite surface when schizonts mature in the presence of protease inhibitors. J Immunol (1986) 1.54
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
Inhibition of in vitro growth of Plasmodium falciparum by immune serum from monkeys. J Infect Dis (1981) 1.37
Two alleles of the 175-kilodalton Plasmodium falciparum erythrocyte binding antigen. Mol Biochem Parasitol (1993) 1.35
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Evidence for two-stage binding by the 175-kD erythrocyte binding antigen of Plasmodium falciparum. J Exp Med (1993) 1.26
A newly described activity of guinea pig IgG1 antibodies: transfer of cutaneous basophil reactions. J Immunol (1978) 1.21
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form. Mol Biochem Parasitol (1992) 1.20
Studies on the role of red blood cell glycoproteins as receptors for invasion by Plasmodium falciparum merozoites. Mol Biochem Parasitol (1982) 1.18
Selective stage-specific changes in the permeability to small hydrophilic solutes of human erythrocytes infected with Plasmodium falciparum. Mol Biochem Parasitol (1985) 1.16
Inhibitory effects of immune monkey serum on synchronized Plasmodium falciparum cultures. Am J Trop Med Hyg (1981) 1.12
Monoclonal antibody characterization of Plasmodium falciparum antigens in immune complexes formed when schizonts rupture in the presence of immune serum. J Immunol (1987) 1.11
Plasmodium falciparum: further characterization of a functionally active region of the merozoite invasion ligand EBA-175. Exp Parasitol (1994) 1.09
Plasmodium falciparum antigens synthesized by schizonts and stabilized at the merozoite surface by antibodies when schizonts mature in the presence of growth inhibitory immune serum. J Immunol (1986) 1.05
Antibody-mediated basophil accumulations in cutaneous hypersensitivity reactions of guinea pigs. J Immunol (1976) 1.03
Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med (2001) 1.00
Determinants on surface proteins of Plasmodium knowlesi merozoites common to Plasmodium falciparum schizonts. J Exp Med (1980) 0.99
Cuta neous basophil responses in neonatal guinea pigs: active immunization, hapten specific transfer with small amounts of serum, and preferential elicitation with phytohemagglutinin skin testing. J Immunol (1977) 0.98
Localization of the major Plasmodium falciparum glycoprotein on the surface of mature intraerythrocytic trophozoites and schizonts. Mol Biochem Parasitol (1984) 0.98
The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol (1988) 0.97
Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol (1987) 0.96
Decreased growth of Plasmodium falciparum in red cells containing haemoglobin E, a role for oxidative stress, and a sero-epidemiological correlation. Trans R Soc Trop Med Hyg (1986) 0.92
Cultured Plasmodium falciparum used as antigen in a malaria indirect fluorescent antibody test. Am J Trop Med Hyg (1978) 0.91
Serotypes of Plasmodium falciparum defined by immune serum inhibition of in vitro growth. Bull World Health Organ (1985) 0.90
Specific basophil hypersensitivity induced by skin testing and transferred using immune serum. Nature (1975) 0.87
Neural correlates of perceptual filling-in of an artificial scotoma in humans. Proc Natl Acad Sci U S A (2007) 0.87
Identification of Plasmodium knowlesi erythrocyte binding proteins. Mol Biochem Parasitol (1988) 0.87
Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19). Am J Trop Med Hyg (1998) 0.81
Protein disulfide isomerase assisted protein folding in malaria parasites. Int J Parasitol (2006) 0.81
Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother (1988) 0.80
Plasmodium falciparum: chymotryptic-like proteolysis associated with a 101-kDa acidic-basic repeat antigen. Exp Parasitol (1992) 0.80
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am J Trop Med Hyg (1996) 0.78
Characterization of gp195 processed products purified from Plasmodium falciparum culture supernates. Mol Biochem Parasitol (1987) 0.78
Polyamine oxidase in human retroplacental serum inhibits the growth of Plasmodium falciparum. Am J Trop Med Hyg (1986) 0.78
Worldwide virtual temperatures for product stability testing. J Pharm Sci (1971) 0.78
Recognition of red cells by malaria parasites: the role of erythrocyte-binding proteins. Transfus Med Rev (1991) 0.77
Serotypic antigens of Plasmodium falciparum recognized by serotype-restricted inhibitory human sera. Am J Trop Med Hyg (1987) 0.77
Extracting the dynamics of perceptual switching from 'noisy' behaviour: an application of hidden Markov modelling to pecking data from pigeons. J Physiol Paris (2001) 0.76
Ultrastructure and viability of cryopreserved Plasmodium falciparum. Bull World Health Organ (1977) 0.75
The Journal and the Press. Can Med Assoc J (1964) 0.75
Absorption kinetics of orally administered leucovorin calcium. NCI Monogr (1987) 0.75
Letter: Content uniformity. J Pharm Sci (1974) 0.75
Gas gangrene septicemia. A late complication of portacaval shunt. Int Surg (1969) 0.75
Wounds of the Myocardium. Can Med Assoc J (1960) 0.75
Evidence for multistability in the visual perception of pigeons. Vision Res (2000) 0.75
Noncompartmental determination of the absorption rate constant. J Pharm Sci (1986) 0.75
Statistical simulation study of new proposed uniformity requirement for bioequivalency studies. J Pharm Sci (1981) 0.75